Showing results (231-240 of 238) with videos related to

Sort By:
Pageof 24
You have reached the last page of results.This site can display upto 238 results.
BMC Medicine|September 29, 2023
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysisYaxin Liu, Wei Wang, Rutie Yin, et al.
Nature Cell Biology|January 31, 2025
SNORD113-114 cluster maintains haematopoietic stem cell self-renewal via orchestrating the translation machineryHui Wang, Zhaoru Zhang, Chenxi Han, et al.
Nature Communications|November 10, 2021
rRNA biogenesis regulates mouse 2C-like state by 3D structure reorganization of peri-nucleolar heterochromatinHua Yu, Zhen Sun, Tianyu Tan, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 21, 2023
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III TrialHuiping Li, Yan Huang, Zhendong Chen, et al.
Nature Microbiology|February 3, 2025
Shigella infection is facilitated by interaction of human enteric α-defensin 5 with colonic epithelial receptor P2Y11Dan Xu, Mengyao Guo, Xin Xu, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 11, 2025
Comparison of efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: A subgroup analysis of a randomized, double-blinded phase III studyYaxin Liu, Ruyan Zhang, Xiaojia Wang, et al.
Circulation|March 24, 2025
Natural History and Clinical Outcomes of Patients With <i>DSG2/DSC2</i> Variant-Related Arrhythmogenic Right Ventricular CardiomyopathyLiang Chen, Yuxiao Hu, Ardan M Saguner, et al.
The Lancet. Oncology|November 27, 2025
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trialHuiping Li, Jieqiong Liu, Quchang Ouyang, et al.
Pageof 24